Thrombolysis with a novel modified tissue-type plasminogen activator, monteplase, combined with catheter-based treatment for major pulmonary embolism

Circulation Journal

Volumn 73, Issue 1, 2009, Pages 106-110

  Yamamoto, Takeshi ^a   Murai, Koji ^a   Tokita, Yukichi ^a   Kato, Koji ^a   Iwasaki, Yu Ki ^a   Sato, Naoki ^a   Tajima, Hiroyuki ^a   Mizuno, Kyoichi ^a   Tanaka, Keiji ^a  

^a NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

Author keywords

Modified tissue type plasminogen activator; Pulmonary embolism; Thrombolysis

Indexed keywords

HEPARIN; MONTEPLASE; UROKINASE; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CATHETERIZATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART RATE; HEART RIGHT VENTRICLE OVERLOAD; HUMAN; LUNG ARTERY PRESSURE; LUNG EMBOLISM; MALE; SHOCK; SYSTOLIC BLOOD PRESSURE; THROMBECTOMY;

ADULT; AGED; CATHETERIZATION, SWAN-GANZ; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; THROMBECTOMY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 58549105501     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0660     Document Type: Article

References (30)

1. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358: 1037-1052.
2. Kucher N, Rossi E, Rosa MD, Goldhaber SZ. Massive pulmonary embolism. Circulation 2006; 113: 577-582.
3. Sakuma M, Nakamura M, Takahashi T, Kitamukai O, Yazu T, Yamada N, et al. Pulmonary embolism is an important cause of death in young adults. Circ J 2007; 71: 1765-1770.
4. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511.
5. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: A meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-749.
6. Kawai C, Yui Y, Hosoda S, Nobuyoshi M, Suzuki S, Sato H, et al. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: Comparison with native t-PA. J Am Coll Cardiol 1997; 29: 1447-1453.
7. Sze DY, Carey MBL, Razavi MK. Treatment of massive pulmonary embolism with catheter-directed tenecteplase. J Vasc Interv Radiol 2001; 12: 1456-1457.
8. Kline JA, Hernandez-Nino J, Jones AE. Tenecteplase to treat pulmonary embolism in the emergency department. J Thromb Thrombolysis 2007; 23: 101-105.
9. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol 1997; 30: 1165-1171.
10. Guidelines on diagnosis and management of acute pulmonary embolism: Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21: 1301-1336.
11. Diehl JL, Meyer G, Igual J, Collignon MA, Giselbrecht M, Even P, et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992; 70: 1477-1480.
12. Sharma GV, McIntyre KM, Sharma S, Sasahara AA. Clinical and hemodynamic correlates in pulmonary embolism. Clin Chest Med 1984; 5: 421-437.
13. Hsu JT, Chu CM, Chang ST, Cheng W, Lin PC, Hsu TS, et al. Prognostic value of arterial/alveolar oxygen tension ratio (a/APO2) in acute pulmonary embolism. Circ J 2007; 71: 1560-1566.
14. Yamamoto T, Sato N, Tajima H, Takagi H, Morita N, Akutsu K, et al. Differences in the clinical course of acute massive and submassive pulmonary embolism. Circ J 2004; 68: 988-992.
15. Tajima H, Murata S, Kumazaki T, Nakazawa K, Abe Y, Komada Y, et al. Hybrid treatment of acute massive pulmonary thromboembolism: Mechanical fragmentation with a modified rotating pigtail catheter, local fibrinolytic therapy, and clot aspiration followed by systemic fibrinolytic therapy. Am J Roentgenol 2004; 183: 589-595.
16. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
17. Meneveau N, Ming LP, Seronde MF, Mersin N, Schiele F, Caulfield F, et al. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J 2003; 24: 1447-1454.
18. Sakuma M, Nakamura M, Nakanishi N, Miyahara Y, Tanabe N, Yamada N, et al. Inferior vena cava filter is a new additional therapeutic option to reduce mortality from acute pulmonary embolism. Circ J 2004; 68: 816-821.
19. Nass N, McConnell MV, Goldhaber SZ, Chyu S, Solomon SD. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. Am J Cardiol 1999; 83: 804-806.
20. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-349.
21. Tagami H, Utoh J, Sun LB, Okamoto K, Moriyama S, Kunimoto R, et al. Effects of recombinant tissue-type plasminogen activator on life-threatening acute pulmonary thromboembolism in a canine model: A comparative study of E6010 and alteplase. Ann Thorac Cardiovasc Surg 2000; 6: 299-303.
22. Konstantinides SV. Acute pulmonary embolism revisited. Heart 2008; 94: 795-802.
23. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: One-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 1999; 99: 1325-1330.
24. Grifoni S, Vanni S, Magazzini S, Olivotto I, Conti A, Zanobetti M, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med 2006; 166: 2151-2156.
25. Meyer G, Gisselbrecht M, Diehl JL, Journois D, Sors H. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105: 472-477.
26. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry. Circulation 1997; 96: 882-888.
27. Stein PD. Thrombolytic therapy in acute pulmonary embolism. In: Stein PD, editor. Pulmonary embolism, 2nd edn. Massachusetts: Blackwell Publishing; 2007; 425-436.
28. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-722.
29. Verstraete M. Third-generation thrombolytic drugs. Am J Med 2000; 109: 52-58.
30. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997; 134: 69-72.